report stellar quarter beat abroad
germani particularli strong guidanc well st
given ou strength feel exceed
lot like includ growth potenti europ asia rp
roll-out margin new product oper excel thing
question share trade ntm revenu said
see much derail suspect compani keep exceed
expect share may continu ralli though feel
comfort recommend valuat meaning progress
stemi dtu studi complet earlier expect may lead
present tct fall could expand market
less posit view propos chang medicar
reimburs feel materi impact y/i growth
rate neutral valuation-bas bull market
expect result remain robust share could keep climb
ou shine arigato japan impella revenu
better model higher ou sale deliv
upsid forecast japan nearli year exceed
mgmt guidanc germani show littl sign deceler
grow y/i quarter believ geographi well
addit eu countri start matter soon
stemi dtu enrol complet earlier expect
enrol pt feasibl studi
expect complet mid-to-l summer vs octob
broader pipelin management commit date
ecp platform expand compani market
rais revenu forecast
valuat maintain neutral rate risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
compani report world-wide impella revenu reflect
improv y/i impella revenu better
forecast impella patient util support
growth protect pci shock meanwhil ou impella
revenu forecast compani continu
see rapid uptak germani japan overal seem driver
gross margin vs last year y/i pressur attribut
manufactur invest intend support futur top-lin growth
sg spend higher model major
increas due invest new products/enhanc clinic cost
relat stemi dtu cvad studi overal ebit margin
bit ligher model despit lower ep
boost lower tax rate reform new stock-bas comp
rais revenu slightli impella increas
revenu estim come better ou sale model roughli
germani sale japan sale new
revenu forecast previous
actualsbtig estimate varianceu impella sale trial impella sale revenu net incom bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
margin model ebit margin reflect continu
oper leverag told ep forecast move
rate neutral feel compani above-averag revenu
growth industry-lead gross margin support premium multipl
peer share ntm revenu estim fewer near-
term catalyst move materi higher feel share least fairli
valu btig provid price target neutral-r stock risk
includ reimburs slippag product timelin chang procedur
patent litig futur devic data fda possibl multipl
exhibit comp tabl fast-grow med-tech compani
impella sale impella sale net incom btig estim compani filingsnewold changentm inc ingnnot factset data btig estimatesintra-day price ptpricemarket cap bp/e ex-amortev/salescagr
abiom incom product fund total y/i good gross sg amort intangibles- total oper incom loss invest incom incom incom expens pre-tax incom incom gaap net incom gaap share non-gaap non-gaap non-gaap ex select calendar loss net product product product oper ep btig estim compani report
abiom revenu commercialnew impella unit asp stock impella cp cp unit cp asp cp stock impella unit asp stock impella rp rp unit rp asp rp stock stock y/i consol instal rate new growth impella y/i inventori inventori impella impella product trial impella impella product product y/i product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
